The research suggests that maintaining hydroxychloroquine (HCQ) blood levels between 750-1200 ng/mL can lead to a 71% lower odds of active lupus and a 26% reduction in flare-ups over 9 months. Guidelines for HCQ dosing may not align with efficacy needs, emphasizing the importance of personalized dosing. Monitoring HCQ blood levels is crucial, especially for patients with chronic kidney disease (CKD) stage 3 or higher. The study highlights the need for individualized dosing to maximize efficacy and minimize toxicity risks.
Til et andet sprog
fra kildeindhold
www.medscape.com
Vigtigste indsigter udtrukket fra
by Marcia Frell... kl. www.medscape.com 09-12-2023
https://www.medscape.com/viewarticle/996340Dybere Forespørgsler